Pfizer announced that it is abandoning development of fibromyalgia drug esreboxetine and an experimental treatment for anxiety -- both in late-stage studies -- to concentrate on higher-potential programs after finding that the drugs did not provide "significant benefit over other therapies." Meanwhile, the company said it will continue efforts to obtain regulatory approval for Lyrica to treat anxiety.

Full Story:
Reuters, Google

Related Summaries